NeoStem
420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

Overview

Stock Quote

  • Robust, diversified pipeline based on proprietary technologies
  • Immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for Phase 3 program in metastatic melanoma and near-term development milestones
  • Cell therapeutic applicable for multiple cardiovascular indications with ongoing Phase 2 study for acute myocardial infarction
  • Immunomodulation therapeutic platform targeting type 1 diabetes and other autoimmune disorders
  • Bicoastal capabilities innovating discovery, development, manufacturing, and delivery of cell-based therapies
  • Highly experienced management and scientific team

Investor Events

Press Releases

Investor Presentation

DOWNLOAD THE PRESENTATION IN PDF FORMAT »